Ketogenic Diet Enhances Mebendazole Therapy in Pediatric High-Grade Glioma (Cell Reports Medicine, 2026)

Key Takeaway
A June 2026 study in Cell Reports Medicine found that combining mebendazole with a ketogenic diet significantly reduced tumor invasion and prolonged survival in juvenile mouse models of high-grade glioma. The ketogenic diet appeared to act as a "metabolic vehicle" that enhanced drug efficacy and allowed lower drug doses — reducing toxicity. This is preclinical research in mice; no human clinical trial data are available yet.

Pediatric high-grade gliomas (HGGs) — including glioblastoma — are among the most devastating childhood cancers, with median survival measured in months despite aggressive surgery, radiation, and chemotherapy. Current treatments carry significant long-term toxicities in developing brains, making the search for better-tolerated alternatives especially urgent.

A study published in June 2026 in Cell Reports Medicine (Cell Press) investigated whether a ketogenic diet (KD) could enhance the anti-tumor effects of mebendazole (MBZ) — a repurposed anthelmintic drug — and devimistat (CPI-613), a mitochondrial metabolism inhibitor, in juvenile mouse models of high-grade glioma. The research was led by Purna Mukherjee and colleagues at Boston College.

The findings suggest that nutritional ketosis creates a metabolic environment that amplifies the effects of both drugs, allowing lower doses to achieve greater tumor suppression — a potentially important finding for reducing treatment toxicity in pediatric patients.

Table of Contents

• Study Background
• How the Ketogenic Diet Helps
• Key Findings
• Mebendazole's Mechanism in Glioma
• Evidence Level and Limitations
• FAQ
• Shop Sanare Lab
• References

Study Background

The study used two established mouse glioma models: VM-M3 (a mesenchymal-origin, highly invasive tumor that spreads throughout the brain and spinal cord) and CT-2A (a neural stem cell-derived, less invasive model). Both models were implanted in juvenile syngeneic mice — meaning the mice had intact immune systems, which is important for evaluating immunological aspects of treatment response.

The researchers also tested mebendazole and devimistat in the human pediatric glioma cell line SF-188, providing an additional layer of translational relevance.

Model	Type	Invasiveness
VM-M3	Mesenchymal-origin glioblastoma	Highly invasive (brain + spinal cord)
CT-2A	Neural stem cell-derived glioblastoma	Less invasive
SF-188	Human pediatric glioma cell line	In vitro (cell culture)

How the Ketogenic Diet Helps

The ketogenic diet — very low in carbohydrates, high in fat — shifts the body's primary fuel source from glucose to ketone bodies. Glioblastoma cells are highly dependent on glucose for energy (the Warburg effect), and they have limited ability to metabolize ketones efficiently. This metabolic vulnerability is the theoretical basis for using KD as an adjunct to cancer therapy.

In this study, the ketogenic diet appeared to work synergistically with mebendazole in several ways:

• Glucose restriction: KD reduces circulating glucose, starving tumor cells that rely on glycolysis
• Mebendazole's glycolysis inhibition: MBZ was found to inhibit glycolysis and glutaminolysis in VM-M3 cells, complementing the glucose restriction imposed by KD
• Lower drug doses needed: The KD-enabled metabolic environment allowed effective tumor suppression at lower drug concentrations, potentially reducing toxicity
• Reduced tumor invasion: The combination produced the greatest reductions in tumor invasion and progression compared to either intervention alone

Key Findings

The study's primary findings, as reported by the authors:

Finding	Detail
Greatest tumor invasion reduction	Occurred with MBZ + KD combination
Prolonged survival	MBZ + KD combination outperformed single interventions
MBZ mechanism in VM-M3	Inhibited glycolysis and glutaminolysis
MBZ in SF-188 (human cells)	Reduced proliferation and viability
Dose reduction potential	KD allowed lower drug dosing with maintained efficacy

The VM-M3 model — the highly invasive mesenchymal glioblastoma — showed the most dramatic response to the combination, which is particularly relevant because invasive glioblastoma is the most clinically challenging subtype.

Mebendazole's Mechanism in Glioma

Mebendazole is a benzimidazole anthelmintic, structurally related to fenbendazole. Its proposed anti-cancer mechanisms include:

• Microtubule disruption: MBZ binds to tubulin and inhibits microtubule polymerization, disrupting cell division
• Metabolic inhibition: As shown in this study, MBZ inhibits glycolysis and glutaminolysis — two key energy pathways in glioblastoma
• Blood-brain barrier penetration: MBZ has demonstrated ability to cross the blood-brain barrier, which is critical for brain tumor treatment
• VEGFR2 inhibition: MBZ has been shown to inhibit angiogenesis by targeting VEGFR2, potentially limiting tumor blood supply

The Johns Hopkins University group has previously conducted a Phase I clinical trial of mebendazole in glioblastoma patients (NCT01729260), establishing safety and tolerability in humans. The current preclinical study adds metabolic context to those earlier findings.

Evidence Level and Limitations

This is a preclinical study in mouse models and cell lines. Key limitations include:

• No human data: The study does not include human patients. Mouse glioma models, while useful, do not fully replicate human glioblastoma biology.
• Juvenile mice only: The study specifically used juvenile (young) mice to model pediatric disease. Results may not apply to adult glioblastoma.
• Ketogenic diet compliance: In human patients, strict ketogenic diet adherence is challenging, particularly in children undergoing cancer treatment.
• Devimistat (CPI-613) status: Devimistat has had mixed results in human clinical trials for other cancers; its role in glioma treatment remains investigational.
• Combination complexity: Three-way combinations (KD + MBZ + devimistat) are difficult to optimize and study in clinical settings.

Evidence level: promising preclinical data supporting further investigation of metabolically informed diet-drug strategies for pediatric gliomas. The authors themselves call for further investigation.

For background, see our guide to how fenbendazole compares with mebendazole.

We cover this in more depth in our article on fenbendazole in brain cancer and glioblastoma.

Estimate a weight-based regimen with our protocol calculator.

Frequently Asked Questions

---

Shop Sanare Lab

Lab-tested products referenced in the research above. Links are provided for convenience — always review the label and consult a professional before use.

Disclaimer: Links are informational and for convenience. This site does not provide medical advice and does not endorse any specific vendor. Always verify product quality, labeling, and consult a licensed professional for health decisions.

References

1. Mukherjee P, Maurer J, Stopka SA, Greenwood B, et al. Ketogenic diet as a metabolic vehicle enhancing the therapeutic efficacy of mebendazole and devimistat in juvenile syngeneic high-grade glioma. Cell Reports Medicine. 2026 Jun. DOI: 10.1016/j.xcrm.2026.102845. PubMed: 42302750.
2. Bai RY, Staedtke V, Aprhys CM, Gallia GL, Riggins GJ. Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme. Neuro-Oncology. 2011;13(9):974-982. DOI: 10.1093/neuonc/nor077.
3. Seyfried TN, Mukherjee P, Iyikesici MS, et al. Consideration of Ketogenic Metabolic Therapy as a Complementary or Alternative Approach for Managing Breast Cancer. Frontiers in Nutrition. 2020;7:21. DOI: 10.3389/fnut.2020.00021.

Medical Disclaimer

This article is for educational and informational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.